REGULATORY MECHANISMS OF PROSTATE TUMOR PROGRESSION

异常的情况或前列腺构成了一个主要的医学问题 美国。前列腺炎、良性肥大(BPH)和恶性 前列腺(CAP)的生长，将影响大多数男性的生活 年仅50岁。BPH是一种令人不安的异常生长，幸运的是它很容易 受到各种选择的对待。前列腺癌，如果及早发现的话 是可以治愈的。然而，转移性疾病可能是致命的，因为目前有 目前尚无转移性前列腺癌的有效治疗方法。此外, 因为在生物潜能方面的极端异质性 前列腺癌的治疗方法存在争议，即使是在 地方性疾病。缺乏共识和可行的方法来 CAP的管理和治疗。这反映了我们缺乏知识。 关于导致这一光谱的生物决定因素 行为水平能够提供适当的治疗 干预。 奥布莱恩泌尿外科中心的这个项目将把注意力集中在 确定与以下因素相关的细胞表型变化 疾病从正常到癌前病变，再到局部病变 癌症，以及远距离传播的疾病。在这个项目中，我们将 集中在与细胞信号和细胞周期相关的三个领域 编程，因为它与良性和恶性前列腺生长有关。 第一个项目将致力于细胞周期调控的研究。 在前列腺癌进展中的作用。第二个项目将检查 PKC同工酶信号转导在肿瘤转移过程中的变化 细胞凋亡性死亡第三个项目将研究PSM的作用 在前列腺生物学中作为叶酸水解酶的抗原及其 进化为癌症。这些项目和发展项目的招募 该中心的计划旨在帮助您了解 CAP进展的生物学与发展强大的理性认识 创新的干预策略。

Abnormal conditions or the prostate constitute a major medical problem in the United States. Prostatitis, benign enlargement (BPH), and malignant growth of the prostate (CaP), will effect the lives of most men over the age of 50. BPH is a bothersome abnormal growth that fortunately is readily treated by a variety of options. Prostate cancer, if detected early is curable. However, metastatic disease can be fatal, as there is currently no available curative therapy for metastatic prostate cancer. In addition, because of the extreme heterogeneity with regard to the biologic potential of prostatic cancer, there is debate on the approach to therapy, even with localized disease. There is a lack of consensus and viable approaches to management and therapy for CaP. This reflects our lack of knowledge regarding the biologic determinants responsible for this spectrum of behavior at a level that would provide appropriate therapeutic intervention. This O'Brien Urology Center project will focus its attention on determining changes in the cellular phenotype that is associated with disease progression from normal to premalignant lesions, to localized cancer, and to distant disseminated disease. In this project we will center on three areas related to cellular signaling and cell cycle programming as it related to benign and malignant prostate growth. The first project will focus its research efforts on cell cycle regulation in prostate cancer progression. The second project will examine alterations in PKC isozyme signaling in metastatic progression and in apoptotic cell death. The third project will examine the role of PSM antigen as a folate hydrolase in the biology of the prostate and its evolution to cancer. These projects and the recruitment of developmental programs to the Center are designed to provide an understanding of the biology of progression of CaP and developing strong rational for innovative interventional strategies.